Sharathchandra S Hegde - Net Worth and Insider Trading

Sharathchandra S Hegde Net Worth

The estimated net worth of Sharathchandra S Hegde is at least $2 Million dollars as of 2024-11-13. Sharathchandra S Hegde is the SVP, Research of Theravance Biopharma Inc and owns about 264,444 shares of Theravance Biopharma Inc (TBPH) stock worth over $2 Million. Details can be seen in Sharathchandra S Hegde's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Sharathchandra S Hegde has not made any transactions after 2019-03-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Sharathchandra S Hegde

Sharathchandra S Hegde Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Sharathchandra S Hegde owns 1 companies in total, including Theravance Biopharma Inc (TBPH) .

Click here to see the complete history of Sharathchandra S Hegde’s form 4 insider trades.

Insider Ownership Summary of Sharathchandra S Hegde

Ticker	Comapny	Transaction Date	Type of Owner
TBPH	Theravance Biopharma Inc	2019-03-05	SVP & Research

Sharathchandra S Hegde Latest Holdings Summary

Sharathchandra S Hegde currently owns a total of 1 stock. Sharathchandra S Hegde owns 264,444 shares of Theravance Biopharma Inc (TBPH) as of March 5, 2019, with a value of $2 Million.

Latest Holdings of Sharathchandra S Hegde

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TBPH	Theravance Biopharma Inc	2019-03-05	264,444	8.91	2,356,196

Holding Weightings of Sharathchandra S Hegde

Sharathchandra S Hegde Form 4 Trading Tracker

According to the SEC Form 4 filings, Sharathchandra S Hegde has made a total of 0 transactions in Theravance Biopharma Inc (TBPH) over the past 5 years. The most-recent trade in Theravance Biopharma Inc is the sale of 9,033 shares on March 5, 2019, which brought Sharathchandra S Hegde around $223,205.

Insider Trading History of Sharathchandra S Hegde

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Sharathchandra S Hegde Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Sharathchandra S Hegde Ownership Network

Ownership Network List of Sharathchandra S Hegde

No Data

Ownership Network Relation of Sharathchandra S Hegde

Sharathchandra S Hegde Owned Company Details

What does Theravance Biopharma Inc do?

Who are the key executives at Theravance Biopharma Inc?

Sharathchandra S Hegde is the SVP & Research of Theravance Biopharma Inc. Other key executives at Theravance Biopharma Inc include 10 percent owner Eli Samaha , SVP & Comm & Medical Affairs Rhonda Farnum , and SVP & Development Richard A Graham .

Theravance Biopharma Inc (TBPH) Insider Trades Summary

Over the past 18 months, Sharathchandra S Hegde made no insider transaction in Theravance Biopharma Inc (TBPH). Other recent insider transactions involving Theravance Biopharma Inc (TBPH) include a net sale of 16,734 shares made by Richard A Graham , a net sale of 10,229 shares made by Rhonda Farnum , and a net purchase of 2,498,924 shares made by Eli Samaha .

In summary, during the past 3 months, insiders sold 0 shares of Theravance Biopharma Inc (TBPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 26,963 shares of Theravance Biopharma Inc (TBPH) were sold and 2,498,924 shares were bought by its insiders, resulting in a net purchase of 2,471,961 shares.

Theravance Biopharma Inc (TBPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Theravance Biopharma Inc Insider Transactions

No Available Data

Sharathchandra S Hegde Mailing Address

Above is the net worth, insider trading, and ownership report for Sharathchandra S Hegde. You might contact Sharathchandra S Hegde via mailing address: 901 Gateway Blvd, South San Francisco Ca 94080.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.